1.00
0.75
0.50
0.25
0.00
0
100
200
300
400
500
PFS probability
Days from randomization
Progression-free survival (PFS)
Events,
n
(%)
120 (88.2)
65 (95.6)
Median, months
3.2
1.7
HR [95% CI]
0.311 [0.222 ‒ 0.435]
P
< 0.0001 (1-sided)
Regorafenib
(
n
=136)
Placebo
(
n
=68)
69% reduction in risk of progression
or death in the regorafenib group
J. Li, et al. WCGI 2014. Abstract O-0023. Presented at WCGI 2014, Barcelona, Spain
